A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be ...
Apr 15, 2013
0
0
Hardening of the arteries, or atherosclerosis, is the primary cause of heart disease. It is caused by calcium accumulation in the blood vessels, which leads to arteries becoming narrow and stiff, obstructing blood flow and ...
Apr 9, 2013
1
3
(Medical Xpress)—Before all the excitement about embryonic stem cells, doctors were using hematopoetic – that is, blood-forming—stem cells. Hematopoetic stem cells can replenish all the types of cells in the blood, ...
Jan 4, 2013
0
0
(Medical Xpress)—In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to ...
Nov 21, 2012
0
0
(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).
Oct 26, 2012
0
0
E. Donnall Thomas, a physician who pioneered bone marrow transplants and later won the 1990 Nobel Prize in medicine, has died in Seattle at age 92.
Oct 21, 2012
0
0
One of the world's leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. ...
Oct 17, 2012
0
0
(Medical Xpress)—Michigan State University researchers have unlocked secrets in bone marrow that could lead to improved treatments for colitis and Crohn's disease.
Sep 24, 2012
0
0
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, ...
Sep 20, 2012
0
0
Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research ...
Sep 10, 2012
0
0
